Global PD-L1 Biomarker Testing Market Research Report, Competitive, Technology and Forecast Analysis 2025-2032
Description
Market Overview
According to DIResearch's in-depth investigation and research, the global PD-L1 Biomarker Testing market size will reach 4,123.24 Million USD in 2025 and is projected to reach 31,177.06 Million USD by 2032, with a CAGR of 33.51% (2025-2032). Notably, the China PD-L1 Biomarker Testing market has changed rapidly in the past few years. By 2025, China's market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
PD-L1 (Programmed Cell Death Ligand 1) biomarker testing is a diagnostic procedure used in oncology to determine the level of PD-L1 protein expression on the surface of cancer cells. It plays a crucial role in the field of cancer immunotherapy, particularly in the treatment of solid tumors with immune checkpoint inhibitors. The test involves analyzing tissue samples from a patient's tumor to assess the presence and degree of PD-L1 expression. The results of PD-L1 biomarker testing help oncologists and clinicians predict the patient's potential response to immunotherapies that target the PD-1/PD-L1 pathway. Higher PD-L1 expression is often associated with a better response to these treatments, making it a valuable tool in personalized cancer care by guiding treatment decisions and improving the effectiveness of immunotherapy for patients with certain types of cancer.
The major global suppliers of PD-L1 Biomarker Testing include Agilent Technologies, Roche, Merck, Bristol-Myers Squibb, AstraZeneca, Ono Pharmaceutical, Regeneron, Innovent, Hengrui Medicine, Junshi Biosciences, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of PD-L1 Biomarker Testing. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major suppliers, as well as the market status and trends of different product types and applications in the global PD-L1 Biomarker Testing market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the PD-L1 Biomarker Testing market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of PD-L1 Biomarker Testing industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Suppliers of PD-L1 Biomarker Testing Include:
Agilent Technologies
Roche
Merck
Bristol-Myers Squibb
AstraZeneca
Ono Pharmaceutical
Regeneron
Innovent
Hengrui Medicine
Junshi Biosciences
PD-L1 Biomarker Testing Product Segment Include:
PD-L1 (22C3)
PD-L1(28-8)
PD-L1 (SP142)
PD-L1 (SP263)
Others
PD-L1 Biomarker Testing Product Application Include:
Hospital
Diagnostic Center
Others
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global PD-L1 Biomarker Testing Industry PESTEL Analysis
Chapter 3: Global PD-L1 Biomarker Testing Industry Porter's Five Forces Analysis
Chapter 4: Global PD-L1 Biomarker Testing Major Regional Market Size (Revenue) and Forecast Analysis
Chapter 5: Global PD-L1 Biomarker Testing Competitive Analysis of Key Suppliers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 6: Global PD-L1 Biomarker Testing Revenue and Forecast Analysis by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 8: Industrial Chain Analysis, PD-L1 Biomarker Testing Different Application Market Analysis (Revenue and Forecast) and Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
According to DIResearch's in-depth investigation and research, the global PD-L1 Biomarker Testing market size will reach 4,123.24 Million USD in 2025 and is projected to reach 31,177.06 Million USD by 2032, with a CAGR of 33.51% (2025-2032). Notably, the China PD-L1 Biomarker Testing market has changed rapidly in the past few years. By 2025, China's market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
PD-L1 (Programmed Cell Death Ligand 1) biomarker testing is a diagnostic procedure used in oncology to determine the level of PD-L1 protein expression on the surface of cancer cells. It plays a crucial role in the field of cancer immunotherapy, particularly in the treatment of solid tumors with immune checkpoint inhibitors. The test involves analyzing tissue samples from a patient's tumor to assess the presence and degree of PD-L1 expression. The results of PD-L1 biomarker testing help oncologists and clinicians predict the patient's potential response to immunotherapies that target the PD-1/PD-L1 pathway. Higher PD-L1 expression is often associated with a better response to these treatments, making it a valuable tool in personalized cancer care by guiding treatment decisions and improving the effectiveness of immunotherapy for patients with certain types of cancer.
The major global suppliers of PD-L1 Biomarker Testing include Agilent Technologies, Roche, Merck, Bristol-Myers Squibb, AstraZeneca, Ono Pharmaceutical, Regeneron, Innovent, Hengrui Medicine, Junshi Biosciences, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of PD-L1 Biomarker Testing. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major suppliers, as well as the market status and trends of different product types and applications in the global PD-L1 Biomarker Testing market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the PD-L1 Biomarker Testing market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of PD-L1 Biomarker Testing industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Suppliers of PD-L1 Biomarker Testing Include:
Agilent Technologies
Roche
Merck
Bristol-Myers Squibb
AstraZeneca
Ono Pharmaceutical
Regeneron
Innovent
Hengrui Medicine
Junshi Biosciences
PD-L1 Biomarker Testing Product Segment Include:
PD-L1 (22C3)
PD-L1(28-8)
PD-L1 (SP142)
PD-L1 (SP263)
Others
PD-L1 Biomarker Testing Product Application Include:
Hospital
Diagnostic Center
Others
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global PD-L1 Biomarker Testing Industry PESTEL Analysis
Chapter 3: Global PD-L1 Biomarker Testing Industry Porter's Five Forces Analysis
Chapter 4: Global PD-L1 Biomarker Testing Major Regional Market Size (Revenue) and Forecast Analysis
Chapter 5: Global PD-L1 Biomarker Testing Competitive Analysis of Key Suppliers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 6: Global PD-L1 Biomarker Testing Revenue and Forecast Analysis by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 8: Industrial Chain Analysis, PD-L1 Biomarker Testing Different Application Market Analysis (Revenue and Forecast) and Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
Table of Contents
165 Pages
- 1 PD-L1 Biomarker Testing Market Overview
- 1.1 Product Definition and Statistical Scope
- 1.2 PD-L1 Biomarker Testing Product by Type
- 1.2.1 PD-L1 (22C3)
- 1.2.2 PD-L1(28-8)
- 1.2.3 PD-L1 (SP142)
- 1.2.4 PD-L1 (SP263)
- 1.2.5 Others
- 1.3 PD-L1 Biomarker Testing Product by Application
- 1.3.1 Hospital
- 1.3.2 Diagnostic Center
- 1.3.3 Others
- 1.4 Global PD-L1 Biomarker Testing Market Size Analysis (2020-2032)
- 1.5 PD-L1 Biomarker Testing Market Development Status and Trends
- 1.5.1 PD-L1 Biomarker Testing Industry Development Status Analysis
- 1.5.2 PD-L1 Biomarker Testing Industry Development Trends Analysis
- 2 PD-L1 Biomarker Testing Market PESTEL Analysis
- 2.1 Political Factors Analysis
- 2.2 Economic Factors Analysis
- 2.3 Social Factors Analysis
- 2.4 Technological Factors Analysis
- 2.5 Environmental Factors Analysis
- 2.6 Legal Factors Analysis
- 3 PD-L1 Biomarker Testing Market Porter's Five Forces Analysis
- 3.1 Competitive Rivalry
- 3.2 Threat of New Entrants
- 3.3 Bargaining Power of Suppliers
- 3.4 Bargaining Power of Buyers
- 3.5 Threat of Substitutes
- 4 Global PD-L1 Biomarker Testing Market Analysis by Country
- 4.1 Global PD-L1 Biomarker Testing Market Size Analysis by Country: 2024 VS 2025 VS 2032
- 4.1.1 Global PD-L1 Biomarker Testing Revenue Analysis by Country (2020-2025)
- 4.1.2 Global PD-L1 Biomarker Testing Revenue Forecast Analysis by Country (2026-2032)
- 4.2 United States PD-L1 Biomarker Testing Market Revenue and Growth Rate (2020-2032)
- 4.3 Germany PD-L1 Biomarker Testing Market Revenue and Growth Rate (2020-2032)
- 4.4 Japan PD-L1 Biomarker Testing Market Revenue and Growth Rate (2020-2032)
- 4.5 China PD-L1 Biomarker Testing Market Revenue and Growth Rate (2020-2032)
- 4.6 France PD-L1 Biomarker Testing Market Revenue and Growth Rate (2020-2032)
- 4.7 U.K. PD-L1 Biomarker Testing Market Revenue and Growth Rate (2020-2032)
- 4.8 South Korea PD-L1 Biomarker Testing Market Revenue and Growth Rate (2020-2032)
- 4.9 Canada PD-L1 Biomarker Testing Market Revenue and Growth Rate (2020-2032)
- 4.10 Italy PD-L1 Biomarker Testing Market Revenue and Growth Rate (2020-2032)
- 4.11 Russia PD-L1 Biomarker Testing Market Revenue and Growth Rate (2020-2032)
- 4.12 Mexico PD-L1 Biomarker Testing Market Revenue and Growth Rate (2020-2032)
- 4.13 Brazil PD-L1 Biomarker Testing Market Revenue and Growth Rate (2020-2032)
- 4.14 India PD-L1 Biomarker Testing Market Revenue and Growth Rate (2020-2032)
- 4.15 Vietnam PD-L1 Biomarker Testing Market Revenue and Growth Rate (2020-2032)
- 4.16 Thailand PD-L1 Biomarker Testing Market Revenue and Growth Rate (2020-2032)
- 4.17 South Africa PD-L1 Biomarker Testing Market Revenue and Growth Rate (2020-2032)
- 5 Competition by Suppliers
- 5.1 Global PD-L1 Biomarker Testing Market Revenue by Key Suppliers (2021-2025)
- 5.2 PD-L1 Biomarker Testing Competitive Landscape Analysis and Market Dynamic
- 5.2.1 PD-L1 Biomarker Testing Competitive Landscape Analysis
- 5.2.2 Global Key Suppliers Headquarter and Key Area Sales
- 5.2.3 Market Dynamic
- 6 PD-L1 Biomarker Testing Market Analysis by Type
- 6.1 Global PD-L1 Biomarker Testing Market Size Analysis by Type: 2024 & 2025 & 2032
- 6.2 Global PD-L1 Biomarker Testing Revenue and Forecast Analysis by Type (2020-2032)
- 7 Key Companies Analysis
- 7.1 Agilent Technologies
- 7.1.1 Agilent Technologies Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.1.2 Agilent Technologies PD-L1 Biomarker Testing Product Portfolio
- 7.1.3 Agilent Technologies PD-L1 Biomarker Testing Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.2 Roche
- 7.2.1 Roche Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.2.2 Roche PD-L1 Biomarker Testing Product Portfolio
- 7.2.3 Roche PD-L1 Biomarker Testing Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.3 Merck
- 7.3.1 Merck Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.3.2 Merck PD-L1 Biomarker Testing Product Portfolio
- 7.3.3 Merck PD-L1 Biomarker Testing Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.4 Bristol-Myers Squibb
- 7.4.1 Bristol-Myers Squibb Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.4.2 Bristol-Myers Squibb PD-L1 Biomarker Testing Product Portfolio
- 7.4.3 Bristol-Myers Squibb PD-L1 Biomarker Testing Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.5 AstraZeneca
- 7.5.1 AstraZeneca Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.5.2 AstraZeneca PD-L1 Biomarker Testing Product Portfolio
- 7.5.3 AstraZeneca PD-L1 Biomarker Testing Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.6 Ono Pharmaceutical
- 7.6.1 Ono Pharmaceutical Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.6.2 Ono Pharmaceutical PD-L1 Biomarker Testing Product Portfolio
- 7.6.3 Ono Pharmaceutical PD-L1 Biomarker Testing Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.7 Regeneron
- 7.7.1 Regeneron Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.7.2 Regeneron PD-L1 Biomarker Testing Product Portfolio
- 7.7.3 Regeneron PD-L1 Biomarker Testing Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.8 Innovent
- 7.8.1 Innovent Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.8.2 Innovent PD-L1 Biomarker Testing Product Portfolio
- 7.8.3 Innovent PD-L1 Biomarker Testing Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.9 Hengrui Medicine
- 7.9.1 Hengrui Medicine Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.9.2 Hengrui Medicine PD-L1 Biomarker Testing Product Portfolio
- 7.9.3 Hengrui Medicine PD-L1 Biomarker Testing Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.10 Junshi Biosciences
- 7.10.1 Junshi Biosciences Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.10.2 Junshi Biosciences PD-L1 Biomarker Testing Product Portfolio
- 7.10.3 Junshi Biosciences PD-L1 Biomarker Testing Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 8 Industry Chain Analysis
- 8.1 PD-L1 Biomarker Testing Industry Chain Analysis
- 8.2 PD-L1 Biomarker Testing Product Downstream Application Analysis
- 8.2.1 Global PD-L1 Biomarker Testing Market Size and Growth Rate (CAGR) by Application: 2024 & 2025 & 2032
- 8.2.2 Global PD-L1 Biomarker Testing Revenue and Forecast by Application (2020-2032)
- 8.3 PD-L1 Biomarker Testing Typical Downstream Customers
- 8.4 PD-L1 Biomarker Testing Sales Channel Analysis
- 9 Research Findings and Conclusion
- 10 Methodology and Data Source
- 10.1 Methodology/Research Approach
- 10.2 Research Scope
- 10.3 Benchmarks and Assumptions
- 10.4 Date Source
- 10.4.1 Primary Sources
- 10.4.2 Secondary Sources
- 10.5 Data Cross Validation
- 10.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
